Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

por Culig, Z, Hoffmann, J, Erdel, M, Eder, I E, Hobisch, A, Hittmair, A, Bartsch, G, Utermann, G, Schneider, M R, Parczyk, K, Klocker, H
Publicado 1999